Genes expressed in C3A liver cell cultures treated with steroids

• US 6,673,549 B1
• Filed: 10/12/2001
• Issued: 01/06/2004
• Est. Priority Date: 10/12/2000
• Status: Expired due to Fees

• Current Assignee: Incyte Genomics, Inc. (Incyte Corporation)
• Original Assignee: Incyte Corporation
• Inventors: Buchbinder, Jenny L., Furness, L. Michael
• Primary Examiner(s): Marschel, Ardin H.
• Assistant Examiner(s): Smith, Carolyn L
• Application Number:
  US09/976,594
• Time in Patent Office: 816 Days
• Field of Search: 536/23.1, 514/44, 435/6, 435/287.2, 435/7.1
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6809 Methods for determination or identification of nucleic acids involving differential detection
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2537/143 Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis

Abstract

The present invention relates to a combination comprising a plurality of cDNAs which are differentially expressed in human C3A liver cell cultures treated with steroids or synthetic steroid analogues and which may be used entirely or in part to detect metabolic and toxicological responses to treatment with steroids and steroid antagonists, to diagnose, to stage, to treat, or to monitor the treatment of a subject with an steroid responsive disorder.

Claims

1. A combination comprising a plurality of cDNAs wherein the plurality of cDNAs are differentially expressed in response to steroid treatment and consist of the nucleic acid sequences of SEQ ID NOs:

1-3, 5, 6, 8, 9, 11-14, 16-18, 20, 21, 23-34, 36, 38-40, 42-50, 52-63, 65, 66, 68-71, 73-75, 77-84, 86-111, 113-115, 117-126, 128-142, 145-160, 162-164, 166, 167, 169-172, 174-176, 178-186, 188-197, 199-202, 204-211, 213, 215, 217-228, 230-246, 248-251, 253-259, 261-266, 268-277, 279, 281, 283, 284, 286, 288-292, 294, 295, 297-300, 302-308, 310, 311, 313, 315-320, 322, 323, 325, 327-346, 348-350, 352-357, 359-368, 370-372, 374, 376, 378, 380-389, 391-400, 402, 403, 405-413, 415, 416, 418, 420, 422-426, 428, 429, 431-446, 448, 450-453, 455, 457, 459, 461, 463-466, 468-470, 472-478, 480-488, 490-492, 494-502, 504-506, 508-520, 522-526, 528-530, 532, 534, 535, 537-561, 563-565, 567, 569-575, 577, 579-581, 583, 585-589, 591-614, 616, 618, 619, 621, 623, 625, 627, 629-641, 643, 645-654, 656-663, 665-680, 682-698, 700-708, 710, 712-720, 722-725, 727-730, 732, 734, 735, 737-741, 743-754, 756, 758-768, 770-780, 782-786, 788-792, 794, 796-802, 804-806, 808, 809, 811-814, 816, 817, 819-829, 831, 833, 835, 836, 838-840, 842-888, 890-892, 894-908, 910, 912, 914-927, 929, 930, 932-937, 939-944, 946, 948-957, 959-964, 966-976, 978-988, 990-999, 1001-1008, 1010-1028, 1030-1034, 1036-1085, 1087-1096, 1098-1143 or a plurality of cDNAs consisting of the complements thereof.

2. The combination of claim 1, wherein the cDNAs are immobilized on a substrate.

3. A high throughput method for using a cDNA to detect differential expression of nucleic acids in a sample, the method comprising:

a) hybridizing the combination of claim 1 with nucleic acids of the sample, thereby forming one or more hybridization complexes;

b) detecting the hybridization complexes; and

c) comparing the hybridization complexes with those of a standard, wherein differences between the standard and sample hybridization complexes indicate differential expression of cDNAs in the sample.

4. The method of claim 3, where in the nucleic acids of the sample are amplified prior to hybridization.

5. The method of claim 3, wherein the sample is from a subject with Wilson disease and comparison with a standard defines a stage of that disease.

6. A high throughput method of screening a plurality of molecules or compounds to identify a ligand which specifically binds a cDNA, the method comprising:

a) combining the combination of claim 1 with the plurality of molecules or compounds under conditions to allow specific binding; and

b) detecting specific binding between each cDNA and at least one molecule or compound, thereby identifying a ligand that specifically binds to each cDNA.

7. The method of claim 6 wherein the plurality of molecules or compounds are regulatory proteins.